Notably, various exendin-4-based GLP-1RAs (Exenatide: 39 aa and Lixisenatide: 44 aa), and GLP-1-based GLP-1RAs (Dulaglutide: 31 aa, Liraglutide: 31 aa, Semaglutide: 31 aa, Tirzepatide: 39 aa, and Albiglutide: 60 aa) have been developed and approved by the FDA between 2005 and 2022 for the management of T2DM (Liu, 2024)
For more information about our programs and services, please contact us at Skyway Behavioral Health.
While drowsiness is often expected and can be managed by taking the medication before bedtime, it may persist into the following day for some individuals
No, photosensitivity is not listed as a known adverse effect in FDA prescribing information for tirzepatide (Mounjaro or Zepbound)
Cusanovich DA, Pavlovic B, Pritchard JK, Gilad Y